Two newly identified sites in the N-terminal regulatory domain of Aurora-A are essential for auto-inhibition

Biotechnol Lett. 2014 Aug;36(8):1595-604. doi: 10.1007/s10529-014-1516-3. Epub 2014 Mar 30.

Abstract

Aurora-A, a centrosome-localized serine/threonine kinase, is over-expressed in multiple human cancers. We previously reported Zhang et al. (Biochem Biophys Res Commun 2007, 357:347-352) intramolecular inhibitory regulation of Aurora-A between its N-terminal (Nt) regulatory domain (amino acids 1-128, Nt) and C-terminal catalytic domain (aa 129-403, Cd). Here, we identified two essential sites located on the Nt of Aurora-A (Lys 99 and Lys 119) and demonstrate that mutation of either residue to Gly could cause the Nt and C-terminal lobes of the catalytic domain in Aurora-A to form a closed conformation, resulting in a loss of kinase activity. This inactive conformation was reversed by adding C26 peptide (274-299) or Ajuba, which is a required activator of Aurora-A. Over-expression of either mutant induced G2/M arrest. These results provide a basis for future anti-cancer studies targeting Aurora-A.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Sequence
  • Amino Acids / metabolism
  • Aurora Kinase A / antagonists & inhibitors*
  • Aurora Kinase A / chemistry*
  • Aurora Kinase A / metabolism
  • Binding Sites
  • Cell Cycle Checkpoints
  • Enzyme Activation
  • HEK293 Cells
  • HeLa Cells
  • Humans
  • LIM Domain Proteins / metabolism
  • Molecular Sequence Data
  • Mutant Proteins / chemistry
  • Mutant Proteins / metabolism
  • Peptides / metabolism
  • Protein Structure, Tertiary
  • Structure-Activity Relationship

Substances

  • Amino Acids
  • LIM Domain Proteins
  • Mutant Proteins
  • Peptides
  • Aurora Kinase A